Tirzepatide and Pregnancy: What the Label and the Evidence Say

If you take tirzepatide (sold as Zepbound for obesity and Mounjaro for type 2 diabetes) and you are pregnant, trying to conceive, or breastfeeding, the guidance is clear and you should not have to dig for it: tirzepatide is not recommended in pregnancy, and the FDA-approved label instructs that it be stopped when a pregnancy is recognized. This is a high-stakes topic, so this page quotes the label rather than paraphrasing loosely, separates what the label actually says from what the human safety data show, and is explicit about where the evidence is thin. None of it is medical advice — it is a map of the official guidance and the published evidence to take to your own clinician.

What the FDA label says: discontinue when pregnancy is recognized

The Zepbound prescribing information is direct. In its Use in Specific Populations section it states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and it advises pregnant patients that weight loss is not recommended during pregnancy and to discontinue Zepbound when a pregnancy is recognized¹. That is the operative instruction: if you become pregnant on tirzepatide, the label tells you to stop it and contact your clinician.

The label's reasoning rests on two things. First, animal reproduction studies of tirzepatide showed adverse developmental effects at clinically relevant exposures, and there are no adequate, well-controlled studies establishing safety in human pregnancy¹. Second — and this is the part people miss — the purpose of the drug conflicts with pregnancy: deliberate weight loss is not a goal during gestation, so there is no upside to weigh against the unknown risk¹. (The Mounjaro label carries the same population guidance for the diabetes indication.)

Breastfeeding: limited data, individualized decision

For lactation, the Zepbound label reports that the concentration of tirzepatide in breast milk was found to be either undetectable or low relative to the maternal dose¹. But "low in milk" is not the same as "proven safe for a nursing infant." There are no data on tirzepatide's effects on a breastfed infant or on milk production, so the label frames breastfeeding as a benefit-versus-risk decision to make with a clinician, weighing the mother's clinical need against potential infant exposure¹. Independent reviews of the GLP-1 class in pregnancy and lactation reach the same cautious conclusion: the lactation data are too limited to call it established-safe, and decisions should be individualized⁵.

The "washout" question: why stopping early matters

A common and reasonable question is how far ahead of trying to conceive should I stop? Here, honesty matters: the FDA label does not specify a pre-conception washout period. What it does give you is the pharmacology to reason from. Tirzepatide has a long elimination half-life of approximately 5 to 6 days¹, and a drug is generally considered effectively cleared after about five half-lives. That arithmetic — roughly four to six weeks — is why many clinicians advise stopping tirzepatide on the order of one to two months before actively trying to conceive, so the drug is largely out of your system during the earliest, most vulnerable weeks of organ development. Treat that as half-life-based clinical reasoning and as guidance echoed by drug regulators such as the UK's MHRA for the GLP-1 class — not as a number printed in the US label. The exact timing is a conversation for your prescriber, who can also plan how to manage your weight or diabetes in the interim; for the general considerations around coming off the drug, see stopping tirzepatide.

What the human safety data actually show

Because few people deliberately take tirzepatide while pregnant, most human evidence comes from inadvertent early-pregnancy exposures — people who conceived while on a GLP-1 drug and stopped once they found out. That evidence is reassuring-but-limited, and it is mostly about the GLP-1 class rather than tirzepatide specifically.

A large US cohort study using insurance data examined people with type 2 diabetes exposed to GLP-1 receptor agonists in early pregnancy and did not find a clear increase in major congenital malformations compared with insulin². A multicentre prospective cohort drawing on six Teratology Information Services reached a broadly similar reassuring signal for first-trimester GLP-1 exposure, while emphasizing the small numbers involved³. And a 2025 review in a major obstetrics journal summarized the field the same way: the available data on GLP-1 receptor agonists in pregnancy are limited and do not currently demonstrate a strong teratogenic signal, but they are not sufficient to declare these drugs safe, so the standard recommendation remains to avoid them in pregnancy⁴.

The crucial caveat for this site: most of those studies pooled GLP-1 agonists generally, and tirzepatide — a dual GIP/GLP-1 agonist — is newer, so its pregnancy-specific human dataset is thinner still. A 2026 systematic review focused on GLP-1 and dual GLP-1/GIP agonists across preconception, pregnancy, and lactation underscored exactly that: the maternal, fetal, and neonatal data remain sparse, and the prudent default is non-use⁵. So the honest read is: the early signal is not alarming, but it is not a green light — it is precisely why both the label and reviewers say to avoid tirzepatide in pregnancy rather than "it's probably fine."

The fertility twist: tirzepatide can make pregnancy more likely

There is a reason contraception matters more on tirzepatide, not less. Effective weight loss can restore ovulation in people who were not ovulating regularly — for example, many with PCOS — which can lead to unplanned pregnancy, the widely reported "Ozempic baby" phenomenon across the GLP-1 class. Tirzepatide drives substantial weight loss in its pivotal obesity trial⁶, and that metabolic improvement is exactly what can re-establish fertility. We unpack this in tirzepatide for PCOS, fertility & "Ozempic babies".

This collides with a second, label-mandated problem: tirzepatide can make oral birth control less effective, because it slows gastric emptying and reduces absorption of the pill⁷. The label therefore instructs people on oral contraceptives to add a barrier method or switch to a non-oral method for four weeks after starting and after each dose increase¹. Put together: a drug that can quietly raise your fertility while lowering the reliability of oral birth control is one where careful contraceptive planning is essential if you are not trying to conceive. The full breakdown is in Zepbound, birth control, and pregnancy.

What to actually do

• •If you discover you are pregnant on tirzepatide, stop it and contact your clinician — that is the label's instruction, not a judgment call¹.
• •If you are planning a pregnancy, talk to your prescriber about stopping ahead of time. Given the ~5–6 day half-life, many clinicians suggest stopping roughly one to two months before trying — but confirm the timing and your interim plan with them¹.
• •If you could become pregnant and aren't trying, use reliable contraception — ideally a non-oral method, given the label's oral-contraceptive warning¹⁷.
• •For breastfeeding, decide with your clinician — milk levels appear low, but infant-safety data are lacking¹⁵.

The honest bottom line

Tirzepatide is not for use in pregnancy. The FDA label says weight loss offers no benefit and may cause fetal harm, and to discontinue the drug when pregnancy is recognized¹. The human safety data — mostly from inadvertent GLP-1-class exposures — have not shown a clear malformation signal, but they are limited, tirzepatide-specific data are thinner still, and reviewers uniformly say that is not enough to call it safe²³⁴⁵. The label gives no pre-conception washout number; the ~5–6 day half-life is the basis for the common "stop one to two months before trying" clinical advice¹. And because tirzepatide can restore fertility while making oral contraception less reliable, contraceptive planning is genuinely important⁶⁷. Bring this to your clinician, and start with our tirzepatide evidence guide and best tirzepatide overview for the wider picture.